 | |
| Clinical data | |
|---|---|
| Trade names | Singoserp |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.001.388 |
| Chemical and physical data | |
| Formula | C35H42N2O11 |
| Molar mass | 666.724 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Syrosingopine is a drug, derived fromreserpine. It is used (since about 1960) to treathypertension.[1][2]
A combination of thediabetes drugmetformin and syrosingopine killed tumor cells in blood samples from leukemia patients, while it did not damage blood cells in samples from healthy patients. The combination of metformin and syrosingopine also reduced or eliminated tumors in mice with malignant liver cancer.[3] The drugs interfere with the cancer cells' glucose (i.e. energy) supply and utilization. Cancer cells have much higher energy requirements than normal cells, making them vulnerable when there is a reduction in the available energy supply. Syrosingopine inhibits the degradation of sugars within the cells.[4][medical citation needed]
We report that the anticancer activity of the widely used diabetic drug metformin is strongly potentiated by syrosingopine. Synthetic lethality elicited by combining the two drugs is synergistic and specific to transformed cells.
The antihypertensive drug syrosingopine potentiates the anti-cancer efficacy of metformin.
 | Thisantihypertensive-related article is astub. You can help Wikipedia byexpanding it. |